Modality
ERT
MOA
FcRni
Target
RET
Pathway
Complement
T2D
Development Pipeline
Preclinical
~Jun 2020
→ ~Sep 2021
Phase 1
Dec 2021
→ Jul 2025
Phase 1Current
NCT06893828
764 pts·T2D
2021-12→2025-07·Not yet recruiting
764 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-07-278mo agoInterim· T2D
2026-02-221mo agoBTD· T2D
Trial Timeline
2022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026
P1
Not yet…
Catalysts
Interim
2025-07-27 · 8mo ago
T2D
BTD
2026-02-22 · 1mo ago
T2D
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06893828 | Phase 1 | T2D | Not yet recr... | 764 | NT-proBNP |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-5389 | Roche | Preclinical | RET | |
| ABB-2476 | AbbVie | Phase 1/2 | USP1 | |
| Fixanesiran | AbbVie | Preclinical | RET | |
| BMY-8678 | Bristol-Myers Squibb | Approved | RET | |
| Suracagene | GSK | Phase 3 | PRMT5 | |
| REG-6699 | Regeneron | Phase 2/3 | TIM-3 | |
| VRT-1576 | Vertex Pharma | Phase 2/3 | RET | |
| ARG-3458 | Argenx | Preclinical | RET | |
| Zanufutibatinib | Intra-Cellular | NDA/BLA | CD38 | |
| Nidaratamab | Krystal Biotech | Preclinical | RET |